OREANDA-NEWS. Addex Therapeutics, announced today that the independent life science research firm, LifeSci Capital has issued an equity research report on Addex Therapeutics. The research report highlights the significant potential of Addex portfolio of drug candidates and in particular dipraglurant for Parkinson's disease levodopa-induced dyskinesia.

PD-LID is the most important unmet medical need after a disease-modifying agent for Parkinson's disease. Dipraglurant was awarded orphan drug designation by the US FDA earlier this year and recently completed a receptor occupancy study in collaboration with the Johns Hopkins University and funding from The Michael J. Fox Foundation for Parkinson's Research. LifeSci estimates the US sales of dipraglurant in PD-LID could be as high as US$1.6 billion with a 50% market penetration.

"This equity research report from US based LifeSci Capital provides a useful in depth analysis of the Addex investment case," commented Tim Dyer, CEO of Addex. "With dipraglurant ready to start Phase III in PD-LID and scheduled to start a Phase II POC in focal cervical dystonia, the Addex turnaround is well on track to deliver significant value to our shareholders."

ADX71441, a second Addex drug candidate, recently demonstrated positive results in a non-human primate model of cocaine addiction. This data together with data already generated in nicotine and alcohol use disorder models, shows the broad potential of ADX71441 in these major public health needs.

The full analyst research report is available on www.lifescicapital.com and on Addex website at www.addextherapeutics.com under Investors/downloads/analyst reports.

LifeSci Capital is a research-driven investment bank with deep domain expertise in the life sciences. The firm's service model as a boutique investment bank is unique in that LifeSci exclusively serves emerging life science companies that discover, develop, and commercialize innovative products. LifeSci views its clients as partners, and the firm works closely with them to establish and execute their capital markets strategies. LifeSci's broadly-distributed equity research product is differentiated and provides a deep understanding of its clients' businesses and the opportunities they are addressing.

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a phase IIa POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter phase III for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF).